Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data

References

• Adolph EF. Quantitative relations in the physiological constitutions of mammals. Science 1949; 109: 579–585
   PubMed Web of Science ®Google Scholar
• Boxenbaum H, Ronfeld R. Interspecies pharmacokinetic scaling and the Dedrick plots. American Journal of Physiology 1983; 245: R768–R775
   PubMed Web of Science ®Google Scholar
• Chow HH. A physiologically based pharmacokinetic model of zidovudine (AZT) in the mouse: Model development and scale-up to humans. Journal of Pharmaceutical Sciences 1997; 86: 1223–1228
   PubMedGoogle Scholar
• Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clinical Infectious Diseases 1997; 24(Suppl. 2)S266–S275
   Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 1998; 26: 1–10
   PubMed Web of Science ®Google Scholar
• Dedrick RL. Animal scale-up. Journal of Pharmacokinetics and Biopharmaceutics 1973; 1: 435–461
   PubMedGoogle Scholar
• Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clinical Infectious Diseases 2003; 36(Suppl. 1)S42–S50
   PubMed Web of Science ®Google Scholar
• Efthymiopoulos C, Battaglia R, Benedetti MS. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. Journal of Antimicrobial Chemotherapy 1991; 27: 517–526
   PubMed Web of Science ®Google Scholar
• Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human. Journal of Pharmacology and Experimental Therapeutics 1998; 287: 457–468
   PubMed Web of Science ®Google Scholar
• Kawamoto I, Shimoji Y, Kanno O, Kojima K, Ishikawa K, Matsuyama E, Ashida Y, Shibayama T, Fukuoka T, Ohya S. Synthesis and structure–activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. Journal of Antibiotics 2003; 56: 565–579
   PubMed Web of Science ®Google Scholar
• Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, Spector T. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicokinetics of 5-fluorouracil in humans. Cancer Chemotherapy and Pharmacology 1997; 39: 233–238
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharmaceutics and Drug Disposition 1998; 19: 231–235
   PubMed Web of Science ®Google Scholar
• Koga T, Abe T, Inoue H, Takenouchi T, Kitayama A, Yoshida T, Masuda N, Sugihara C, Kakuta M, Nakagawa M, Shibayama T, Matsushita Y, Hirota T, Ohya S, Utsui Y, Fukuoka T, Kuwahara S. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrobial Agents and Chemotherapy 2005; 49: 3239–3250
   PubMed Web of Science ®Google Scholar
• Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrobial Agents and Chemotherapy 1992; 36: 1810–1816
   PubMed Web of Science ®Google Scholar
• Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. Journal of Pharmacobio-Dynamics 1990; 13: 602–611
   PubMedGoogle Scholar
• Mehta SC, Lu DR. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharmaceutics and Drug Disposition 1995; 16: 735–744
   PubMed Web of Science ®Google Scholar
• Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, Kobayashi T. Prediction of ACNU plasma concentration–time profiles in humans by animal scale-up. Cancer Chemotherapy and Pharmacology 1990; 27: 20–26
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Viani A. Methods of determining plasma and tissue binding of drugs. Pharmacokinetics consequences. Clinical Pharmacokinetics 1992; 23: 449–468
   PubMed Web of Science ®Google Scholar
• Rennecke JT, Hirota T, Shibayama T, Matsushita Y, Kuwahara S, Puchler K, Ruhland A, Drewelow B (2002) Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy;, San Diego, CAUSA, 27–30 September, 2002. American Society for Microbiology, Washington, DC, F-327
   Google Scholar
• Richter WF, Heizmann P, Meyer J, Starke V, Lave T. Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. Journal of Pharmaceutical Sciences 1998; 87: 496–500
   PubMedGoogle Scholar
• Sawada Y, Hanano M, Sugiyama Y, Iga T. Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmaceutics 1984; 12: 241–261
   PubMedGoogle Scholar
• Shibayama T, Matsushita Y, Kikuchi N, Kawai K, Hirota T, Kuwahara S (2000) R-115685, a novel parenteral Carbapenem: Pharmacokinetics and metabolism in laboratory animals. Paper presented at the 40th Interscience Conference on Antibacterial Agents and Chemotherapy, Toronto, Ont.Canada, 17–20 September, 2000. American Society for Microbiology, Washington, DC, F-1233
   Google Scholar
• Takahagi H, Hirota H, Matsushita Y, Muramatsu M, Tanaka M, Matsuo E. In vitro dehydropeptidase-I activity and its hydrolytic activity of panipenem in several tissues in animal species and their influence on the disposition of panipenem in vivo. Chemotherapy (Tokyo) 1991; 39(Suppl. 3)236–241
   Google Scholar
• Thomson KS, Moland ES. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 2004; 54: 557–562
   PubMed Web of Science ®Google Scholar
• Tsuji A, Sato H, Tamai I, Adachi H, Nishihara T, Ishiguro M, Ohnuma N, Noguchi T. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. Drug Metabolism and Disposition 1990; 18: 245–252
   PubMedGoogle Scholar